| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.7 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |